These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11710544)

  • 21. Contractile effect of the chemotactic factors f-Met-Leu-Phe and C5a on the human isolated umbilical artery. Role of cyclooxygenase products and tissue macrophages.
    Marceau F; deBlois D; Laplante C; Petitclerc E; Pelletier G; Grose JH; Hugli TE
    Circ Res; 1990 Nov; 67(5):1059-70. PubMed ID: 1699682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin.
    Chen Z; Zhang X; Gonnella NC; Pellas TC; Boyar WC; Ni F
    J Biol Chem; 1998 Apr; 273(17):10411-9. PubMed ID: 9553099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat.
    Short A; Wong AK; Finch AM; Haaima G; Shiels IA; Fairlie DP; Taylor SM
    Br J Pharmacol; 1999 Feb; 126(3):551-4. PubMed ID: 10188960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant.
    Ulrich JT; Cieplak W; Paczkowski NJ; Taylor SM; Sanderson SD
    J Immunol; 2000 May; 164(10):5492-8. PubMed ID: 10799917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor.
    Cain SA; Coughlan T; Monk PN
    Biochemistry; 2001 Nov; 40(46):14047-52. PubMed ID: 11705397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist.
    Haynes DR; Harkin DG; Bignold LP; Hutchens MJ; Taylor SM; Fairlie DP
    Biochem Pharmacol; 2000 Sep; 60(5):729-33. PubMed ID: 10927032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis.
    Kola A; Baensch M; Bautsch W; Hennecke M; Klos A; Casaretto M; Köhl J
    Immunotechnology; 1996 Jun; 2(2):115-26. PubMed ID: 9373320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Xenopus oocytes the human C3a and C5a receptors elicit a promiscuous response to the anaphylatoxins.
    Ames RS; Nuthulaganti P; Kumar C
    FEBS Lett; 1996 Oct; 395(2-3):157-9. PubMed ID: 8898085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
    Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
    Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.
    Kawai M; Quincy DA; Lane B; Mollison KW; Luly JR; Carter GW
    J Med Chem; 1991 Jul; 34(7):2068-71. PubMed ID: 2066977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin.
    Tempero RM; Hollingsworth MA; Burdick MD; Finch AM; Taylor SM; Vogen SM; Morgan EL; Sanderson SD
    J Immunol; 1997 Feb; 158(3):1377-82. PubMed ID: 9013982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.
    Bubeck P; Grötzinger J; Winkler M; Köhl J; Wollmer A; Klos A; Bautsch W
    Eur J Biochem; 1994 Feb; 219(3):897-904. PubMed ID: 8112341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a potent and orally active non-peptide C5a receptor antagonist.
    Sumichika H; Sakata K; Sato N; Takeshita S; Ishibuchi S; Nakamura M; Kamahori T; Ehara S; Itoh K; Ohtsuka T; Ohbora T; Mishina T; Komatsu H; Naka Y
    J Biol Chem; 2002 Dec; 277(51):49403-7. PubMed ID: 12384495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke.
    Floreani AA; Heires AJ; Welniak LA; Miller-Lindholm A; Clark-Pierce L; Rennard SI; Morgan EL; Sanderson SD
    J Immunol; 1998 May; 160(10):5073-81. PubMed ID: 9590258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a receptor-binding region in the core segment of the human anaphylatoxin C5a.
    Vlattas I; Sytwu II; Dellureficio J; Stanton J; Braunwalder AF; Galakatos N; Kramer R; Seligmann B; Sills MA; Wasvary J
    J Med Chem; 1994 Aug; 37(17):2783-90. PubMed ID: 8064805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
    March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
    Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.
    Halai R; Bellows-Peterson ML; Branchett W; Smadbeck J; Kieslich CA; Croker DE; Cooper MA; Morikis D; Woodruff TM; Floudas CA; Monk PN
    Eur J Pharmacol; 2014 Dec; 745():176-81. PubMed ID: 25446428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a.
    Van Epps DE; Simpson SJ; Johnson R
    J Immunol; 1993 Jan; 150(1):246-52. PubMed ID: 8417126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
    Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
    J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
    Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
    Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.